Background
Noroviruses (NoVs) are the most common cause of epidemic gastroenteritis, responsible for at least 50% of all gastroenteritis outbreaks worldwide and were recently identified as a leading cause of travelers’ diarrhea (TD) in U.S. and European travelers to Mexico, Guatemala and India.
Methods
Serum and diarrheic stool samples were collected from 75 US student travelers to Cuernavaca, Mexico, who developed TD. NoV RNA was detected in acute diarrheic stool samples using RT-PCR. Serology assays were performed using GI.1 Norwalk virus (NV) and GII.4 Houston virus (HOV) virus-like particles (VLP) to measure serum levels of IgA and IgG by Dissociation-Enhanced Lanthanide Fluorescent Immunoassay (DELFIA); serum IgM was measured by capture ELISA, and the 50% antibody blocking titer (BT50) was determined by a carbohydrate-blocking assay.
Results
NoV infection was identified in 12 (16%; 9 GI-NoV and 3 GII-NoV) of 75 travelers by either RT-PCR or ≥4-fold rise in antibody titer. Significantly more individuals had detectable pre-existing IgA antibodies against HOV (62/75, 83%) than against NV (49/75, 65%) (p=0.025) VLPs. A significant difference was observed between NV- and HOV-specific preexisting IgA antibody levels (p=0.0037), IgG (p=0.003) and BT50 (p=<0.0001). None of the NoV-infected TD travelers had BT50 >200, a level that has been described previously as a possible correlate of protection.
Conclusions
We found that GI-NoVs are commonly associated with TD cases identified in U.S. adults traveling to Mexico, and seroprevalence rates and geometric mean antibody levels to a GI-NoV were lower than to a GII-NoV strain.